Compare · AKAN vs DFTX
AKAN vs DFTX
Side-by-side comparison of Akanda Corp. (AKAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 292.0x AKAN ($8.8M).
- Over the past year, AKAN is down 83.2% and DFTX is up 208.4% - DFTX leads by 291.6 points.
- DFTX has been more active in the news (6 items in the past 4 weeks vs 2 for AKAN).
- DFTX has more recent analyst coverage (4 ratings vs 0 for AKAN).
PerformanceAKAN-83.20%DFTX+208.43%
2025-06-04+0.00%2026-06-03
- Company
- Akanda Corp.
- Definium Therapeutics Inc.
- Price
- $16.30-6.38%
- $23.59+3.10%
- Market cap
- $8.8M
- $2.57B
- 1M return
- -60.72%
- +8.48%
- 1Y return
- -83.20%
- +208.43%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 4
AKAN
Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Latest AKAN
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form NT 20-F filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026